🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The objective of the study is to test the efficacy, safety and tolerability...
Status
Completed
Location
1218.6.3302A Boehringer Ingelheim Investigational Site
Start Date
2006-04
Trial ID
NCT00309608
Treatments Being Tested
The aim of the trial is to assess the relative bioavailability of fixed dos...
Status
Completed
Location
1288.5.86001 Boehringer Ingelheim Investigational Site
Start Date
2012-02
Trial ID
NCT01540487
Treatments Being Tested
Assessment of the effect of BI 1356 or Placebo on prolongation of the QT in...
Status
Completed
Location
Multiple Locations
Start Date
2008-01
Trial ID
NCT02183467
Treatments Being Tested
TQ-F3083 capsule is a new type inhibitor of DPP-IV, which is currently a ve...
Status
Unknown
Location
The Second Affiliated Hospital of Chongqing Medical Uversity
Start Date
2020-01-01
Trial ID
NCT03986073
Two independent study parts (i.e. Part A and Part B) are included in this t...
Status
Completed
Location
Tokai Memorial Hospital
Start Date
2015-05-12
Trial ID
NCT02489968
Study to investigate the safety, tolerability, pharmacokinetics, and pharma...
Status
Completed
Location
Multiple Locations
Start Date
2005-08
Trial ID
NCT02183415
Treatments Being Tested
The primary objective of the current study is to investigate the relative b...
Status
Completed
Location
1275.3.1 Boehringer Ingelheim Investigational Site
Start Date
2010-08
Trial ID
NCT01189201
Treatments Being Tested
This trial will evaluate use of BI 10773/linagliptin once daily (qd) fixed ...
Status
Completed
Location
1275.1.01103 Boehringer Ingelheim Investigational Site
Start Date
2011-08
Trial ID
NCT01422876
Treatments Being Tested
The main objective of this study is to identify the dose of linagliptin in ...
Status
Completed
Location
1218.56.01006 Boehringer Ingelheim Investigational Site
Start Date
2011-04
Trial ID
NCT01342484
Treatments Being Tested
To establish the bioequivalence of one fixed dose combination (FDC) tablet ...
Status
Completed
Location
Humanpharmakologisches Zentrum Biberach
Start Date
2017-08-31
Trial ID
NCT03259490
Treatments Being Tested